AU2017228405A1 - Small molecule IRE1-alpha inhibitors - Google Patents
Small molecule IRE1-alpha inhibitors Download PDFInfo
- Publication number
- AU2017228405A1 AU2017228405A1 AU2017228405A AU2017228405A AU2017228405A1 AU 2017228405 A1 AU2017228405 A1 AU 2017228405A1 AU 2017228405 A AU2017228405 A AU 2017228405A AU 2017228405 A AU2017228405 A AU 2017228405A AU 2017228405 A1 AU2017228405 A1 AU 2017228405A1
- Authority
- AU
- Australia
- Prior art keywords
- ring
- compound
- pct
- alkyl
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 35
- 150000003384 small molecules Chemical class 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 166
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 37
- 102100030013 Endoribonuclease Human genes 0.000 claims abstract description 20
- -1 -NH-SO2-phenyl-(R5) Chemical group 0.000 claims description 161
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000004429 atom Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 206010003445 Ascites Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229960002474 hydralazine Drugs 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 7
- 208000019423 liver disease Diseases 0.000 claims description 7
- 230000005976 liver dysfunction Effects 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 claims description 6
- 125000004450 alkenylene group Chemical group 0.000 claims description 6
- 125000004419 alkynylene group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 210000000066 myeloid cell Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 4
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 claims description 4
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 229940125877 compound 31 Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007915 intraurethral administration Methods 0.000 claims description 2
- 239000002997 ophthalmic solution Substances 0.000 claims description 2
- 229940054534 ophthalmic solution Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 claims 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 claims 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims 2
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 claims 2
- 229940125878 compound 36 Drugs 0.000 claims 2
- 229940126540 compound 41 Drugs 0.000 claims 2
- 229940125936 compound 42 Drugs 0.000 claims 2
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 9
- 101710199605 Endoribonuclease Proteins 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 description 40
- 125000003118 aryl group Chemical group 0.000 description 30
- 125000005842 heteroatom Chemical group 0.000 description 25
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 19
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 238000001327 Förster resonance energy transfer Methods 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 description 13
- 102100038151 X-box-binding protein 1 Human genes 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- 108010093099 Endoribonucleases Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 10
- 229940043355 kinase inhibitor Drugs 0.000 description 10
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 229910052794 bromium Inorganic materials 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000006372 lipid accumulation Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 150000001721 carbon Chemical class 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 238000003032 molecular docking Methods 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 108020004518 RNA Probes Proteins 0.000 description 4
- 239000003391 RNA probe Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 230000035578 autophosphorylation Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- DMEGQEWPMXDRMO-UHFFFAOYSA-N 4-phenylpyrimidin-2-amine Chemical compound NC1=NC=CC(C=2C=CC=CC=2)=N1 DMEGQEWPMXDRMO-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 2
- FYGQOHVBUBFDQO-UHFFFAOYSA-N N1CNCC2C1=CCS2 Chemical compound N1CNCC2C1=CCS2 FYGQOHVBUBFDQO-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940122924 Src inhibitor Drugs 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000005426 adeninyl group Chemical group N1=C(N=C2N=CNC2=C1N)* 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000005602 azabenzimidazolyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 2
- 229960001131 ponatinib Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000016914 response to endoplasmic reticulum stress Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000565 sulfonamide group Chemical group 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical class OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- NOHQEAFAESMMDX-UHFFFAOYSA-N 1-[4-(8-amino-3-tert-butylimidazo[1,5-a]pyrazin-1-yl)naphthalen-1-yl]-3-[3-(trifluoromethyl)phenyl]urea Chemical compound C=12C(N)=NC=CN2C(C(C)(C)C)=NC=1C(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC=CC(C(F)(F)F)=C1 NOHQEAFAESMMDX-UHFFFAOYSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150087690 ACTB gene Proteins 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101150097620 TRE1 gene Proteins 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 108010035430 X-Box Binding Protein 1 Proteins 0.000 description 1
- 102000008165 X-Box Binding Protein 1 Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005252 haloacyl group Chemical group 0.000 description 1
- 125000002192 heptalenyl group Chemical group 0.000 description 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000002443 hydroxylamines Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
- NRZWQKGABZFFKE-UHFFFAOYSA-N trimethylsulfonium Chemical compound C[S+](C)C NRZWQKGABZFFKE-UHFFFAOYSA-N 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000004906 unfolded protein response Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Described herein are IRE1a inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application. (Formule I)
Description
invention is a compound of formula I:
wherein:
A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x Ri substituents;
C is phenyl or pyridinyl;
D is heterocyclyl ring;
linkagei is a C1-C5 alkylene, an alkenylene, an alkynylene, an alkylamido, an acyl, or an oxo(carbonyl)alkylene with a first and second terminal atom;
linkage?, is a Ci-Cs alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;
y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;
x is an integer of 0-2; v is an integer of 0-1;
Ri substituents on the A ring are selected from amino, C1-C3 alkyl, ether, alkoxy, oxy, hydroxy, -NH-SO2-phenyl-(Rs), and cyano;
R? substituents on the B ring are selected from amino, and C1-C3 alkyl;
R? substituents on the C ring are selected from CF3, and C1-C3 alkyl; and R4 substituents on the D ring arc selected from C1-C3 alkyl, Ct-Cs alkoxy, benzyl, and benzaldehyde;
Rs is halo; or a pharmaceutically acceptable salt thereof.
[0008] Another aspect is a compound of formula II:
wherein:
E is phenyl;
F is phenyl, naphthalene, tetrahydro naphthalene, or a bicyclic heterocycle; -2WO 2017/152126
PCT/US2017/020792
G is phenyl, or a heterocyclyl ring; heterocycle indene, dihydroindene, or benzodioxole;
linkages is a C1-C3 alkyl, alkylamino, aminoalkyl, alkylaminoaikylene, or amino; linkage4 is aikylamido, amidoaikyl, alkylamidoaikylene;
R2 is amino, or C1-C3 alkyl;
R5 is halo;
R& is Ci-Cs alkyl, Ci-Cs alkoxy, or hydroxy; x is an integer of 0-2; v is an integer of 0-1; or a pharmaceutically acceptable salt thereof.
[0009] Another aspect of the invention is compound selected from any of the compounds in the Examples, or a pharmaceutically acceptable salt thereof.
[0010] Another aspect of the invention is a composition that includes a carrier and any of the compounds of formula I or II, pharmaceutically acceptable salts thereof, or any combination of such compounds.
[0011] Another aspect of the invention is a composition that includes a carrier and any of the compounds in the Examples, pharmaceutically acceptable salts thereof, or any combination thereof.
[0012] Another aspect of the invention is a method that includes administering one or more of such compositions to a mammal. For example, the mammal can be in need of administration of the composition. Such a mammal can, for example, have cancer, a neurodegenerative disease, inflammation, a metabolic disorder, liver dysfunction, brain ischemia, heart ischemia, or an autoimmune disease such as systemic lupus erythematosus. In some cases, the mammal has triple negati ve breast cancer or ovarian cancer.
[0013] The compositions and methods described herein can include one or more agents such as vitamin E, an antioxidant, and/or hydralazine. Such agents can sequester lipid peroxidation byproducts, and can be effective treatments for controlling ER stress responses and sustained IREla/XBPl signaling in tumor-associated dendritic cells exposed, for example, to ovarian cancer-derived ascites.
[0014] The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments of the present invention.
[0015] FIG. 1A is the structure of vitamin E (VitE).
[0016] FIG. IB is the structure of hydralazine (Hiz), a representative member of lipid peroxidation-sequestering hydrazines.
WO 2017/152126
PCT/US2017/020792 [0017] FIG. 1C is RT-qPCR analyses of markers of ER stress after culturing purified tumorresident DCs in the absence (grey bars) or presence (green bars) of 25% cell-free ovarian cancer ascites supernatants for 18 hours. Data are normalized to Actb expression in each sample.
[0018] FIG. ID is flow cytometry analysis of lipid accumulation in mouse bone marrow-derived dendritic cells exposed to the indicated treatments, measured by BODIPY 493/503 staining intensity. Both raw data and quantified geometric mean fluorescence intensity (MFI) are shown. [0019] FIG. 2A is a cartoon of a cleavable RNA probe and IRE la-dependent hairpin cleavage site. In FIG. 2A, the quenching dye is released, fluorescence is emitted.
[0020] FIG. 2B is a cartoon of a point mutation (G —> C) in the hairpin that abrogates IREla activity against RNA probe, controlling for contamination by non-specific RNAses. In FIG. 2B, the quenching dye is retained, and no fluorescence is emitted.
[0021] FIG. 3 is the structure of an IREla inhibitor identified by computational screening and confirmed by human IREla FRET assay (commercially available from InterBioScreen).
[0022] FIG. 4 is the structures of novel IREla inhibitors and their corresponding IC50 values, according to some embodiments.
[0023] FIG. 5 is the structures of novel IREla inhibitors and their corresponding IC50 values, according to some embodiments.
[0024] FIG. 6 is a plot of rate as a function of compound concentration. FIG. 6 shows the inhibitory activity of some embodiments of the inventive compounds against IREla. All members of inhibitor series significantly block IREla endoribonuclease catalytic activity. Raw data analysis of IREla FRET assay results are shown, plotted as rate of fluorescence signal increase over time.
[0025] FIG. 7 are RT-PCR and western blot analyses of IREla inhibitors according to some embodiments. All members of the inhibitor series significantly block IREla endoribonuclease activity and autophosphorylation in cells. Panel A in FIG. 7 illustrates an RT-PCR analysis of Xbpl splicing in human 293FT cells. Cells were treated with the pharmacological ER stressor tunicamycin in the presence or absence of indicated IREla inhibitors for 3 hours. The upper band corresponds to full-length, unspliced Xbpl mRNA, while the lower band represents the shorter, spliced Xbpl mRNA iso form generated by active IREla. Panel B in FIG. 7 illustrates phos-tag western blot analysis of IREla autophosphorylation in 293FT cells treated with tunicamycin in the presence or absence of indicated compounds. The endoribonuclease inhibitor 4u8C and kinase inhibitor KIRA6 are included in each experiment as controls.
[0026] FIG. 8 is a synthetic scheme to synthesize a “building block” base according to an embodiment.
-4WO 2017/152126
PCT/US2017/020792 [0027] FIG. 9 is a synthetic scheme to synthesize Compound 31. Alkyne head groups are generated via a TMS intermediate and then coupled with a copper coil reaction.
[0028] FIG. 10 A is a plot of BODIPY 493/503 mean fluorescence staining intensity (MFI) as a function of IRE la inhibitor concentration. Murine splenic dendritic cells that were incubated with 10% murine ovarian cancer ascites supernatants overnight in the presence or absence of indicated IRE la inhibitors. Lipid accumulation was measured by flow cytometry as BODIPY 493/503 mean fluorescence staining intensity (MFI).
[0029] FIG. 10B is a plot of Prostaglandin E2 secretion as a function of IREla inhibitor concentration. Murine bone marrow-derived dendritic cells were pre-treated for 1 hour with the indicated IREla inhibitors, then stimulated with LPS for 6 hours. Prostaglandin E2 secretion was measured by ELISA in ceil-free supernatants.
Detailed Description [0030] The invention relates to compounds that can modulate the activity of IREla. IREla is a type I transmembrane protein with dual enzymatic activities, including an N-terminal domain that projects into the luminal side of the endoplasmic reticulum (IRE1-LD) and a serine/threonine kinase domain plus a C-terminal ribonuclease (RNase) domain located on the cytosolic side of the protein.
[0031] The compounds of the invention include any of the compounds described herein, in the Examples, and the figures. Embodiments of the invention include but are not limited to one or more compounds of formula I:
wherein:
A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x Ri substituents;
C is phenyl or pyridinyl;
D is heterocyclyl ring;
linkage! is a C1-C5 alkylene, an alkenylene, an alkynylene, an alkylamido, an acyl, or an oxo(carbonyl)alkylene with a first and second terminal atom;
linkage2 is a C1-C3 alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;
WO 2017/152126
PCT/US2017/020792 y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;
x is an integer of 0-2; v is an integer of 0-1;
Ri substituents on the A ring are selected from amino, C3-C3 alkyl, ether, alkoxy, oxy, hydroxy, -NH-SCh-phenyi-fRs), and eyano;
Rs substituents on the B ring are selected from amino, and C1-C3 alkyl;
Rs substituents on the C ring are selected from CFs, and C1-C3 alkyl; and R4 substituents on the D ring are selected from C1-C3 alkyl, Ci-Cs alkoxy, benzyl, and benzaldehyde;
Rs is halo; or a pharmaceutically acceptable salt thereof.
[0032] Embodiments of the invention include but are not limited to one or more compounds of formula 11:
>2>v pinkage-yj Ylinkage^· (RA θ /
A wherein:
F is phenyl, naphthalene, tetrahydronaphthalene, or a bicyclic heterocycle;
G is phenyl, or a heterocyclyl ring; heterocycle indene, dihydroindene, or benzodioxole;
linkages is a C1-C3 alkyl, alkylamino, aminoalkyl, alkylaminoalkylene, or amino; linkage4 is alkylamido, amidoaikyl, alkylamidoaikylene;
Rs is amino, or C1-C3 alkyl;
Rs is halo;
Re is C1-C3 alkyl, C1-C3 alkoxy, or hydroxy: x is an integer of 0-2; v is an integer of 0-1; or a pharmaceutically acceptable salt thereof.
[0033] All structures encompassed within a claim are chemically feasible, by which is meant that the structure depicted by any combination or subcombination of optional substituents meant to be recited by the claim is physically capable of existence with at least some stability as can be
-6WO 2017/152126
PCT/US2017/020792 determined by the laws of structural chemistry and by experimentation. Structures that are not chemically feasible are not within a claimed set of compounds.
[0034] When a substituent is specified to be an atom or atoms of specified identity, or a bond, a configuration is referred to when the substituent is a bond that the groups that are immediately adjacent to the specified substituent are directly connected to each other by a chemically feasible bonding configuration.
[0035] In general, substituted and substituent refers to an organic group as defined herein in which one or more bonds to a hydrogen atom contained therein are replaced by one or more bonds to a non-hydrogen atom such as, but not limited to, a halogen (i.e., halo selected from F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo(carbonyi) groups, carboxyl groups including carboxylic acids, carboxylates, and carboyxlate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxylamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups. Non-limiting examples of substituents that can be bonded to a substituted carbon (or other) atom include F, Cl, Br, I, OR', OC(O)N(R’)2, CN, CF3, OCF3, R’, O, S, C(O), S(O), methylenedioxy, ethylenedioxy, N(R’)2, SR’, SOR’, SO2R’, SO2N(R’)2, SO3R', C(O)R', C(O)C(O)R’, C(O)CH2C(O)R’, C(S)R', C(O)OR', OC(O)R’, C(O)N(R')2, OC(O)N(R')2, C(S)N(R’)2, (CH2)0.2NHC(O)R’, (CH2)0.. 2N(R')N(R')2, N(R')N(R')C(O)R', N(R’)N(R’)C(O)OR', N(R')N(R’)C0N(R')2, N(R')SO2R', N(R’)SO2N(R’)2, N(R')C(O)OR', N(R')C(O)R', N(R')C(S)R’, N(R’)C(O)N(R')2, N(R’)C(S)N(R')2, N(COR’)COR', N(OR’)R’, C(=NH)N(R')2, C(O)N(OR’)R’, or C(=NOR’)R’ wherein R' can be hydrogen or a carbon-based moiety, and wherein tire carbon-based moiety can itself be further substituted. In some cases the R' group is a hydrogen, Ci-Ce alkyl, or phenyl.
[0036] In many of the compounds described herein, the substituents fire selected from amino, CiC3 alkyl, ether, alkoxy, oxy, CF3, and cyano C1-C3 alkoxy, benzyl, and benzaldehyde. The ether and alkoxy groups can have 1-6 carbon atoms.
[0037] Substituted alkyl, alkenyl, alkynyl, cycloalkyl, and cycloalkenyl groups as well as other substituted groups also include groups in which one or more bonds to a hydrogen atom are replaced by one or more bonds, including double or triple bonds, to a carbon atom, or to a heteroatom such as, but not limited to, oxygen in carbonyl (oxo), carboxyl, ester, amide, imide, urethane, and urea groups; and nitrogen in imines, hydroxyimines, oximes, hydrazones, amidines, guanidines, and nitriles.
[0038] Substituted ring groups such as substituted aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond
-7WO 2017/152126
PCT/US2017/020792 to a carbon atom. Therefore, substituted aryl, heterocyclyl and heteroaryl groups can also be substituted with alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and alkynyl groups as defined herein, which can themselves be further substituted.
[0039] The term heteroatoms as used herein refers to non-carbon and non-hydrogen atoms, capable of forming covalent bonds with carbon, and is not otherwise limited. Typical heteroatoms are N, O, and S. When sulfur (S) is referred to, it is understood that the sulfur can be in any of the oxidation states in which it is found, thus including sulfoxides (R-S(O)-R') and sulfones (R-S(O)2-R'), unless the oxidation state is specified; thus, the term sulfone encompasses only the sulfone form of sulfur; the term sulfide encompasses only the sulfide (RS-R') form of sulfur. When the phrases such as hetero atoms selected from the group consisting of O, NH, NR' and S, or [variable] is O, S . . are used, they are understood to encompass all of the sulfide, sulfoxide and sulfone oxidation states of sulfur.
[0040] Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from. 1 to 8 carbon atoms. Examples of straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, nheptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, isobutyl, sec-butyl, t-butyl, neopentyl, isopentvl, and 2,2-dimethylpropyl groups. Representative substituted alkyl groups can be substituted one or more times with any of the groups listed above, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
[0041] Cycloalkyl groups are alkyl groups forming a ring structure, which can be substituted or unsubstituted. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above. Representative substituted cycloalkyl groups can be monosubstituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6disubstituted cyclohexyl groups or mono-, di- or tri-substituted norbornyl or cycloheptyl groups, which can be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
-8WO 2017/152126
PCT/US2017/020792 [0042] The terms carbocyciic and carbocycle denote a ring structure wherein the atoms of the ring are carbon. In some embodiments, the carbocycle has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms is 4, 5, 6, or 7. Unless specifically indicated to the contrary, the carbocyciic ring can be substituted with as many as N substituents wherein N is the size of the carbocyciic ring with for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
[0043] (Cycloalkyl)alkyl groups, also denoted cycloalkylaikyl, are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkyl group as defined above.
[0044] /Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to -CH=CH(CH3), -UH-UiUH j ·.
-C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, vinyl, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
[0045] The term cycloalkenyl alone or in combination denotes a cyclic alkenyl group wherein at least one double bond is present in the ring structure. Cycloalkenyl groups include cycloalkyl groups having at least one double bond between two adjacent carbon atoms. Thus for example, cycloalkenyl groups include but are not limited to cyclohexenyl, cyclopentenyl, and cyclohexadienyl groups.
[0046] (Cycloalkenyl)alkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloaikenyl group as defined above. [0047] Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to OCH, -OC(CH3), -C=C(CH2CH3), -ch2och,
-CH2GhC(CH3), and -CH2CsC(CH2CH3), among others.
[0048] Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms. Thus arylgroups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups. In some embodiments, aryl groups contain 6-14 carbons in the ring portions of the groups. The phrase aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like), .9.
WO 2017/152126
PCT/US2017/020792 and also includes substituted aryl groups that have other groups, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups, bonded to one of the ring atoms. Representative substituted aryl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which can be substituted with groups including but not limited to those listed above.
[0049] Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above. Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4ethyl-indanyl. The aryl moiety or the alkyl moiety or both are optionally substituted with other groups, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups. Araikenyl group are alkenyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
[0050] Heterocyclyl groups include aromatic and non-aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, S, or P. Heteroaryl and heterocyclicalkyl groups are included in the definition of heterocyclyl. In some embodiments, heterocyclyl groups include 3 to 20 ring members, whereas other such groups have 3 to 15 ring members. At least one ring contains a heteroatom, but every ring in a polycyclic system need not contain a heteroatom. For example, a dioxolanyl ring and a benzdioxolanyl ring system (methylenedioxyphenyl ring system) fire both heterocyclyl groups within the meaning herein. A heterocyclyl group designated as a C2-heterocyclyl can he a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth. Likewise a Cr-heterocyclyl can be a 5-ring with one heteroatom, a 6ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms. In some cases, the heterocyclyl is a single ring. In other cases, the heterocyclyl is a fusion of two or three rings. The phrase heterocyclyl group includes fused ring species including those having fused aromatic and nonaromatic groups. The phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl and also includes heterocyclyl groups that have substituents, including hut not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups, bonded to one of the ring members. A heterocyclyl group as defined herein can be a heteroaryl group or a partially or completely saturated cyclic group including at least one ring heteroatom. Heterocyclyl groups include, hut are not limited to, pyrrolidinyl, furanyl, tetrahydrofuranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, henzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl,
-10WO 2017/152126
PCT/US2017/020792 benzimidazolyl, azabenzimidazolyl, benzoxazolyi, benzothiazoiyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Heterocyclyl groups can be substituted. Representative substituted heterocyclyl groups can be mono-substituted or substituted more than once, including but not limited to, rings containing at least one heteroatom which are mono, di, tri, tetra, penta, hexa, or higher-substituted with substituents such as those listed above, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, and alkoxy groups.
[0051] Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. A heteroaryl group designated as a CJ-heteroaryi can be a 5-ring with two carbon atoms and three heteroatoms, a 6ring with two carbon atoms and four heteroatoms and so forth. Likewise a Cq-heteroaryl can be a 5 -ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl, azaindolyi, indazoiyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyi, benzothiazoiyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinoxalinyl, and quinazolinyl groups. The terms heteroaryl and heteroaryl groups include fused ring compounds such as wherein at least one ring, but not necessarily ail rings, are aromatic, including tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl and 2,3-dihydro indolyl. The term also includes heteroaryl groups that have other groups bonded to one of the ring members, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxy, nitro, thio, or alkoxy groups. Representative substituted heteroaryl groups can be substituted one or more times with groups such as those listed above.
[0052] Additional examples of aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl, N-hydroxytriazolyl, N-hydroxyimidazolyl, anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2thienyl, 3-thienyl), furyl (2-furyl, 3-furyl) , indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fiuorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-l-yl, 1,2,3-triazol-2-yl l,2,3-triazol-4-yl, l,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl),
-11WO 2017/152126
PCT/US2017/020792 pyrazinyl, pyridazinyl (3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolyl (2-quinolyl, 3quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (1-isoquinolyl,
3- isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydrobenzo[b]furanyl), 3-(2,3-dihydro-benzo[b]furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2,3dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo [bjthiophenyl (2-benzo[b jthiophenyl, 3-benzo[b]thiopheiiyl, 4-benzo[b]thiophenyl, 5benzo[b]thiophenyl, 6-benzo [bjthiophenyl, 7-benzo[b]thiophenyl), 2,3-dihydrohenzo[b]thiophenyl, (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo [bjthiophenyl),
4- (2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[bjthiophenyl), 6-(2,3-dihydrobenzo[h]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (l-indolyl, 2-indolyl, 3indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl, 4indazolyl, 5-inda.zolyl, 6-indazolyl, 7-indazoiyl), benzimidazoiyl (1-benzimidazolyl, 2henzimidazolyl, 4-benzimidazolyl, 5-benzimidazoiyl, 6-benzimidazoiyl, 7-benzimidazoiyl, 8benzimidazolyl), benzoxazolyl (l-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5Hdibenz[b,f]azepine (5H-dibenz[b,f]azepin-l-yl, 5H-dibenz[b,f]azepine-2-yl, 5Hdihenz[b,fjazepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11dihydro-5H-dibenz[b,f|azepine (10,ll-dihydro-5H-dibenz[b,fjazepine-l-yl, 10,11 -dihydro-5Hdibenz[b,f]azepine-2-yl, 10,ll-dihydro-5H-dibenz[b,i]azepine-3-yl, 10,ll-dihydro-5Hdibenz[b,f]azepine-4-yL 10,ll-dihydro-5H-dibenz[b,f]azepine-5-yl), and the like.
[0053] Heterocyclylalkyl groups are cyclic alkyl groups as defined above in which a. hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Representative heterocyclyl alkyl groups include, but are not limited to, furan-2 -yI methyl, furans'- yl methyl, pyridine-2-yl methyl (a-picolyl), pyridine-3-yl methyl (β-picolyl), pyridine-4-yl methyl (γ-pieolyl), tetrahydrofuran-2-yl ethyl, and indol-2-yl propyl. Heterocyclylalkyl groups can be substituted on the heterocyclyl moiety, the alkyl moiety, or both.
[0054] Heteroarylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Heteroarylalkyl groups can be substituted on the heteroaryl moiety, the alkyl moiety, or both. [0055] By a ring system or ring, as the term is used herein, is meant a moiety comprising one, two, three or more rings, which can be substituted with non-ring groups or with other ring systems, or both, which can be fully saturated, partially unsaturated, fully unsaturated, or
-12WO 2017/152126
PCT/US2017/020792 aromatic, and when the ring system includes more than a single ring, the rings can be fused, bridging, or spirocyclic. By spirocyclic is meant the class of structures wherein two rings are fused at a single tetrahedral carbon atom, as is well known in the art.
[0056] A ''monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring as the term is used herein refers to a ring system including an unsaturated ring possessing 4n+2 pi electrons, or a partially reduced (hydrogenated) form thereof. The aromatic or partially aromatic ring can include additional fused, bridged, or spiro rings that are not themselves aromatic or partially aromatic. For example, naphthalene and tetrahydronaphthalene are both a monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring within the meaning herein. Also, for example, a benzo-[2.2.2]-bicyclooctane is also a monocyclic, bicyclic or polycyclic, aromatic or partially aromatic ring within the meaning herein, containing a phenyl ring fused to a bridged bicyclic system. A fully saturated ring has no double bonds therein, and is carbocyclic or heterocyclic depending on the presence of heteroatoms within the meaning herein.
[0057] The term, alkoxy refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined above. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexvloxy, and the like. Examples of cyclic alkoxy include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0058] The terms aryloxy and arylalkoxy refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom, at the alkyl moiety. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
[0059] An acyl group as the term is used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom, is also bonded to another carbon atom, which can be part of an alkyl, aryl, aralkyl cvcloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl group or the like. In the special case wherein the carbonyl carbon atom is bonded to a hydrogen, the group is a formyl group, an acyl group as the term is defined herein. An acyl group can include 0 to about 12-20 additional carbon atoms bonded to the carbonyl group. An acyl group can include double or triple bonds within the meaning herein. An acryloyl group is an example of an acyl group. An acyl group can also include heteroatoms within the meaning here. A nicotinoyl group (pyridyl-3-carbonyl) group is an example of an acyl group within the meaning herein. Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like. When the group containing the carbon atom that is bonded to the carbonyl carbon
WO 2017/152126
PCT/US2017/020792 atom contains a halogen, the group is termed a haloacyl group. An example is a trifluoroacetyl group.
[0060] The term amine or amino includes primary, secondary, and tertiary amines having, e.g., the formula N(group)3 wherein each group can independently he H or non-H, such as alkyl, aryl, and the like. Amines include but are not limited to R-NH?, for example, alkylamines, arylamines, alkylarylamines; R4NH wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocyclylamines and the like; and R5N wherein each R is independently selected, such as trialkylamines, dialkylarylamines, aikyldiarylamines, triarylamines, and the like. The term amine also includes ammonium ions as used herein. [0061] An amino group is a substituent of the form -NH?, -NHR, -N(R)?, -N(R)3+, wherein each R is independently selected, and protonated forms of each. Accordingly, any compound substituted with an amino group can be viewed as an amine.
[0062] An ammonium ion includes the unsubstituted ammonium ion NHA, hut unless otherwise specified, it also includes any protonated or quatemarized forms of amines. Thus, trimethylammonium hydrochloride and tetramethylammonium chloride are both ammonium, tons, and amines, within the meaning herein.
[0063] The term amide (or amido) includes C- and N-amide groups, i.e, -C(O)N(K)?, and -NRC(O)R- groups, respectively. Amide groups therefore include hut are not limited to carbamoyl groups (-C(O)NH?) and formamide groups (-NHC(O)H). A carboxamido group is a group of the formula C(O)N(R)?, wherein R can be H, alkyl, aryl, etc.
[0064] The term, urethane (or carbamyl) includes N- and O-urethane groups, i.e, NRC(O)OR and -OC(O)N(R)? groups, respectively.
[0065] The term sulfonamide (or sulfonamido) includes S- and N-sulfonamide groups, i.e, SO2NR2 and -NRSO2R groups, respectively. Sulfonamide groups therefore include hut are not limited to sulfamoyl groups (-SO2NH2).
[0066] The term amidine or amidino includes groups of the formula -C(NR)N(R)2.
Typically, an amidino group is -C(NH)NH?.
[0067] The term guanidine or guanidino includes groups of the formula -NRC(NR)N(R)?, Typically, a guanidino group is -NHC(NH)NH2.
Halo, halogen, and halide include fluorine, chlorine, bromine and iodine.
The terms comprising, including, having, composed of, are open-ended terms as used herein, and do not preclude the existence of additional elements or components. In a claim element, use of the forms comprising, including, having, or composed of means that whatever element is comprised, had, included, or composes is not necessarily the only element encompassed by the subject of the clause that contains that word.
14.
WO 2017/152126
PCT/US2017/020792 [0070] A salt as is well known in the art includes an organic compound such as a carboxylic acid, a sulfonic acid, or an amine, in ionic form, in combination with a counterion. For example, acids in their anionic form can form salts with cations such as metal cations, for example sodium, potassium, and the like; with ammonium salts such as NIF' or the cations of various amines, including tetraalkyl ammonium salts such as tetramethylammonium, or other cations such as trimethylsulfonium, and tire like. A pharmaceutically acceptable or pharmacologically acceptable salt is a salt formed from an ion that has been approved for human consumption and is generally non-toxic, such as a chloride salt or a sodium salt. A zwitterion is an internal salt such as can be formed in a molecule that has at least two ionizable groups, one forming an anion and the other a cation, which serve to balance each other. For example, amino acids such as glycine can exist in a zwitterionic form. A zwitterion is a. salt within the meaning herein. The compounds of the present invention may take the form of salts. The term salts embraces addition salts of free acids or free bases which are compounds of the invention. Salts can be pharmaceutically-acceptable salts. The term pharmaceutically-acceptable salt refers to salts which possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present invention, such as for example utility in process of synthesis, purification or formulation of compounds of the invention.
[0071] Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, and phosphoric acids. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric, salicylic, galactaric and galacturonic acid. Examples of pharmaceutically unacceptable acid addition salts include, for example, perchlorates and tetrafluoroborates.
[0072] Suitable pharmaceutically acceptable base addition salts of compounds of the invention include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines such as, for example, A,A-dibenzyiethy!enedia.mine, chloroprocaine, choline,
-15WO 2017/152126
PCT/US2017/020792 diethanolamine, ethylenediamine, meglumine (N-m.ethylgluea.mine) and procaine. Examples of pharmaceutically unacceptable base addition salts include lithium salts and cyanate salts. Although pharmaceutically unacceptable salts are not generally useful as medicaments, such salts may be useful, for example as intermediates in the synthesis of Formula 1 or II compounds, for example in their purification by recrystallization. All of these salts may be prepared by conventional means from the corresponding compound according to Formula 1 or II by reacting, for example, the appropriate acid or base with the compound according to Formula I or II. The term pharmaceutically acceptable salts refers to nontoxic inorganic or organic acid and/or base addition salts, see, for example, Lit et al., Salt Selection for Basic Drugs (1986), bit J. Pharm.,
33, 201-217, incorporated by reference herein.
[0073] A hydrate is a compound that exists in a composition with water molecules. The composition can include water in stoichiometric quantities, such as a monohydrate or a dihydrate, or can include water in random amounts. As the term is used herein a hydrate refers to a solid form, i.e., a compound in water solution, while it may be hydrated, is not a hydrate as the term is used herein.
[0074] A solvate is a similar composition except that a solvent other that water replaces the water. For example, methanol or ethanol can form an alcoholate, which can again be stoichiometric or non-stoichiometric. As the term is used herein a solvate refers to a solid form, i.e., a compound in solution in a solvent, while it may be solvated, is not a solvate as the term is used herein.
[0075] A prodrug as is well known in the art is a substance that can be administered to a patient where the substance is converted in vivo by the action of biochemicals within a mammal's body (e.g., in a patient's body), such as enzymes, to the active pharmaceutical ingredient. Examples of prodrugs include esters of carboxylic acid groups, which can be hydrolyzed by endogenous esterases as are found in the bloodstream of humans and other mammals.
[0076] In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described. Moreover, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any combination of individual members or subgroups of members of Marku sh groups. Thus, for example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, and Y is
WO 2017/152126
PCT/US2017/020792 described as selected from the group consisting of methyl, ethyl, and propyl, claims for X being bromine and Y being methyl are fully described.
[0077] In various embodiments, the compound or set of compounds, either per se or as are used in practice of embodiments of the inventive methods, can be any one of any of the combinations and/or sub-combinations of the various embodiments recited.
[0078] Provisos may apply to any of the disclosed categories or embodiments wherein any one or more of the other above disclosed embodiments or species may be excluded from such categories or embodiments.
[0079] The compounds of the invention include any of those described herein, including compounds shown in the Examples. In some instances, the compounds are embraced by formula pi>>,
A ///
A j-biikageH B / V ^-linkage?·/ c M· H / [0080] In some cases, the A ring of the compounds described herein is heteroaromatic. For example, the A ring can be a fusion of two rings. Examples of A rings include indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrroiopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, and phenylpyrimidinami ne. For example, the A ring can be selected from any of the following:
/Χ.,
N.
X/''
T-N N '7
7' 7 ] I
NH \ .,7-7
WO 2017/152126
PCT/US2017/020792
ana
[0081] The Ri substituents on the A ring can, for example, be selected from amino and C1-C3 alkyl. In some cases, the Ri substituents on the A ring are selected from-NfU and -CH3. In addition, in some cases x=0, but in other cases x=l. For example, x can in some cases be 0 when the A ring is a fusion of two rings. In other cases, x=l or 2 when the A ring is a single, nonfused ring.
[0082] The B ring can he a single, non-fused ring. Alternatively, the B ring can be a fission of two rings. For example, the B ring can he selected from any of the following:
N,
II
---Ή ./
-A,
UN~N and
..A
V.
-N cr
H ,N_
HN
NB /
-'NH /
'V-°
WO 2017/152126
PCT/US2017/020792
The iinkagei can, for example, be selected from:
-o-ox/ -χ.··
H %Υ Y , Y Y h
O
Z\
X.~ X' Χ,χΥΥ
H .x’’ Y
H /V / \x \
and O wherein a hydrogen atom on Ring A is replaced by the first terminal atom of Iinkagei and a hydrogen atom on Ring B is replaced by the second terminal atom of iinkagei.
[0084] In some cases the C ring can be a phenyl group, and in other cases, a pyridinyl group. For example, the R3 substituent on the C ring is CF3.
[0085] The linkage?, group can, for example, be selected from any of the following:
Η H /Y. Yv ,,Y Y^Y ^Y x„
N
J.l\ s
Y· /ζ’'\χΖ and O , wherein a hydrogen atom on Ring B is replaced by the first terminal atom of linkage? and a hydrogen atom on Ring C is replaced by the second terminal atom of linkage?. [0086] The D ring can, for example, be selected from any of the following:
H
XNX.
Y Y
Y. Y
Y
ZZ
WO 2017/152126
PCT/US2017/020792
and tz [0087] The R4 substituents on the D ring can in some cases be selected from CH3, CH3CHCH3, CH3CH(CH2)CH3, and CH3CH2CH3OH.
[0088] Embodiments of the invention include hut are not limited to one or more compounds of formula II:
“linkaKe-Z
Ά'.. z £ i ' 1 [0089] The F ring can, for example, be phenyl, naphthalene, tetrahydronaphthalene, or a bicyclic heterocycle. Such an F bicyclic heterocycle can he a spirodecane where one or two of the ring carbons is nitrogen rather than carbon. For example, an F bicyclic heterocycle can have any of the following structures:
[0090] The G ring can be phenyl, a heterocycle indene, a dihydroindene, or benzodioxole. [0091] In some instances, the compounds are the compounds as shown in Table 1 and Table 2.
TABLE 1
Compound
No.
Structure
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
Γ | |
i Compound llllllllll! | Structure |
A7 | F h2n F|F nKA'.n s firAA / αανΧνΑα Ax Η H |
A8 | F -o F 1 F χΆ /Ν·'·ν o A n\=aAa a XJ kA Η H |
A9 | F #Ά /'•ν o A/XX aj-^-Ua π AX H H |
A10 | F F___L__F ο. /ν~·ν o xXXx a JU xA Η H |
All | F H2N-^A\ _ /N N 0 X? — XananXX X/'k Η H |
A12 | _ /'-ν ο hU OxnAnA^J An\ Η H |
A13 | F ί ' ' i' y-N ο ΑΑΆ LAAJXX^Xj xa Η H |
WO 2017/152126
PCT/US2017/020792
Γ | |
i Compound llllllllll! | Structure |
A14 | F _ z nn o r X-n “ VKnXnAT 0ΑΚ Η H |
A15 | F o F+F / \ /Ν·ν ο X/A/A ν/--\Α a aJ U Η H |
A16 | F \ H1r /''A /N Ο LAMa AU kA Η H |
A17 | F F”t”F Α”Α /Nn ο Χ/Α/δ NM=A”U λ AJ) qA - N N Η H |
A18 | F F_±_F #~A /nn o r Α/Χί·Χ ^ΑΑΛα a AJ kA λAr N' AW \x \ Η H |
A19 | A'ii s π O \=7 ΑΑνΑνΑΑ Anx Η H |
A20 | F -a3 — X a j5 '-f N N Η H |
WO 2017/152126
PCT/US2017/020792
TABLE 2
24'
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
Compound
No.
B8
B9
Structure
\.
TO.
BIO
TOx .·:»·· χ. <>··
\\ %
\
Bll
X
WO 2017/152126
PCT/US2017/020792
Compound No. | Structure |
: .-'rt. L J X, · | |
B12 | , Sa -..--'rt, ..1 v ·.<··* X |
A.—/ | |
ό | |
B13 | IO...... ....... rt., / \ |
.··' :'s” *' \ 1. ./ | |
\'x o | |
.. ^// | |
B14 | ,A,„ A... w |
!> <.....i......s r......fi x .·· x xs | |
A... | |
B15 | I .A*' Ά ... • X ....../ ,/ / |
/A . .···’ ax’' |
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
-31WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
Com pound No. | Structure | |||
x\··' | ||||
W-i { | ||||
B31 | Y | cs XN{·! | ||
..-A-.., | ||||
—Y | % | |||
Yx. | ||||
k X ·<.....'\ | ||||
...,-, .s ..... | ΎΥ | X | ||
Y | ||||
B32 | ||||
Y. ...Ύ | ||||
?Y | ||||
' Y | ||||
A. | ||||
·\.χΎ | ||||
\ / | ||||
B33 | ||||
h.......ί v /· | ||||
* \ | ||||
\ ;q.} | ||||
Y-Y-.γ::.:--γ-λχ.. | ||||
Υ,---:ΥΥ | ||||
,···· \ | ||||
B34 | V | Ϊ | ||
\,;Y | ---4 | YY.Z | ||
/ \x |
..34..
WO 2017/152126
PCT/US2017/020792
Compound
No.
Structure
TO >
V
TO x
B37
WO 2017/152126
PCT/US2017/020792
Com pound No. | Structure |
B38 | 7 7.../ .1 C J , 1...... \ <;··· ·:·:·· .·' \ 'ϊΜ;:·'.·' < > /.......··' |
B39 | ^\...... . A..... Γ 1 xz··· |
B40 | ..•:-‘:>x. 4k .-:· · χ..·:::··· \ x. s > f Ί \ »·· .........(,'l i f /' \ . · V |
B41 | \ Z < / .,J ,··*' \ / ) ? |
WO 2017/152126
PCT/US2017/020792
-37WO 2017/152126
PCT/US2017/020792
Com pound No. | Slroctare |
B45 | VY> 1 Ϊ· J0....... χ;·: · 7<. ,LJ |
B46 | f.·-:-, ·.,/ XJ Y1 ., .... V‘ ' T y'p Ί o >.·· i |
B47 | o XX ' /W x |
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
WO 2017/152126
PCT/US2017/020792
Compound No. | Structure |
\ /'A \ | |
B55 | V ' \ |
A A ? \ | |
B56 | f A A’ A %. A -. X ,:A-·. . .,-'>.: ! '·<·· :-C N |
[0092] More specifically, the inventive compound can be any of the specific examples shown herein as exemplary compounds of the invention.
Methods of Use [0093] The inventors and co workers have recently demonstrated that XBP1 sustains dendritic cell immunosuppressive activity within the tumor microenvironment by directly upregulating enzymes involved in triglyceride biosynthesis (Cubillos-Ruiz et al., Cell 161(7): 1527-38 (2015)). XBP1, also known as X-box binding protein 1, is a transcription factor that regulates the expression of genes involved in the proper functioning of the immune system and in the cellular stress response. The inventors demonstrated that IRE la-mediated XBP1 activation was fueled by the induction of reactive oxygen species and subsequent formation of peroxidized [0094] The most conserved arm of the endoplasmic reticulum (ER) stress response is the dual enzyme, IRE la. Activated during periods of ER stress, the IRE la endoribonuclease domain excises a short nucleotide fragment from Xbpl mRNA to generate the functional transcription factor, XBP1. This potent, multitasking protein promotes cell survival by upregulating expression of a broad range of critical genes in volved in protein folding and quality control. XBP1 drives the pathogenesis of triple negative breast cancer (TNBC) by promoting tumor cell survival and metastatic capacity under hypoxic conditions. Silencing of XBP1 in TNBC leads to suppression of tumor initiation, progression, and recurrence.
WO 2017/152126
PCT/US2017/020792 [0095] Unexpectedly, the inventors have identified a second mechanism by which XBP1 promotes tumor progression: by confounding the development of protective antitumor immunity in the ovarian cancer tumor microenvironment. Without XBP1, tumor resident dendritic cells failed to accumulate intracellular lipids, which normally disrupt effective antigen crosspresentation. This pathological lipid accumulation is fundamentally driven by reactive oxygen species-mediated lipid peroxidation, which directly destabilizes protein-folding chaperones within the endoplasmic reticulum to induce a state of ER stress and XBP1 activation. Additionally, it is believed that 1RE1 «-mediated XBP1 signaling is also critical for myeloid ceil production of immunosuppressive prostaglandins such as prostaglandin E2 (PGE2).
[0096] Novel small-molecule IREla inhibitors with the ability to induce two parallel and mutually reinforcing anti-tumor mechanisms, namely the direct inhibition of tumor growth and the simultaneous induction of robust anti-tumor immunity, are highly desirable, as no effective, targeted therapies currently exist for either TNBC or ovarian cancer. The compositions and methods described herein are novel IREla kinase inhibitors that exhibit immune-modulatory properties. No currently existing compounds possess activity in the presence of human or mouse ovarian cancer ascites, a critical requirement for IREla inhibitor usage clinically.
[0097] Novel direct and indirect small molecule IREla inhibitors can prevent lipid accumulation in myeloid ceils exposed to ovarian cancer-derived ascites supernatants. Furthermore, the identified direct IREla inhibitors have unique chemical structures compared to currently available compounds, and therefore can have unique binding mechanisms, inhibitory activity, and off-target effects. Additionally, the inventors have demonstrated that these compounds block myeloid cell immunosuppression mediated by tumor-associated factors. The invention also includes novel uses for vitamin E and hydralazine derivatives, which indirectly prevent IREla activation and thereby suppress cancer cell-induced lipid accumulation in myeloid dendritic cells. [0098] The TREla-XBPl pathway is therefore involved in a variety of pathological conditions, including neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, heart ischemia, autoimmune diseases, and cancer. Hence, modulation of this pathway provides therapeutic methods useful for treatment of such diseases. The identified small molecule compounds can, for example, be employed as therapeutic compounds that enhance dendritic cell and T cell anti-tumor activity in mammals. For example, the compounds disclosed herein can be used to treat murine and human ovarian cancers.
[0099] Hence, a method is described herein that includes administering any of the compounds or the composition described herein. The mammal can be in need of administration of the composition. For example, the mammal can have cancer, a neurodegenerative disease, inflammation, a metabolic disorder, liver dysfunction, brain ischemia, heart ischemia, or an
-42WO 2017/152126
PCT/US2017/020792 autoimmune disease, in some eases, the mammal has triple negative breast cancer or ovarian cancer.
Compositions and Combination Treatments [0100] The IREla inhibitor compounds, their pharmaceutically acceptable salts or hydrolyzable esters of the present invention may be combined with a pharmaceutically acceptable carrier to provide pharmaceutical compositions useful for treating the biological conditions or disorders noted herein in mammalian species, and more preferably, in humans. The particular carrier employed in these pharmaceutical compositions may vary depending upon the type of administration desired (e.g. intravenous, oral, topical, suppository, or parenteral).
[0101] In preparing the compositions in oral liquid dosage forms (e.g. suspensions, elixirs and solutions), typical pharmaceutical media, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be employed. Similarly, when preparing oral solid dosage forms (e.g. powders, tablets and capsules), carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like can be employed.
[0102] Another aspect of an embodiment of the invention provides compositions of the compounds of the invention, alone or in combination with another IREla inhibitor or another type of therapeutic agent, or both. For example, the compositions and methods described herein can include one or more agents such as vitamin E, an antioxidant, and/or hydralazine. Such agents can sequester lipid peroxidation byproducts, and can be effective treatments for controlling ER stress responses and sustained IREla/XBPl signaling in tumor-associated dendritic cells exposed, for example, to ovarian cancer-derived ascites.
[0103] As set forth herein, compounds of the invention include stereoisomers, tautomers, solvates, hydrates, salts including pharmaceutically acceptable salts, and mixtures thereof. Compositions containing a compound of the invention can be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy, 19th Ed., 1995, incorporated by reference herein. The compositions can appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
[0104] Typical compositions include one or more compounds of the invention and a pharmaceutically acceptable excipient which can be a carrier or a diluent. For example, tire active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which can be in the form, of an ampoule, capsule, sachet, paper, or other container. When the active compound is mixed with a carrier, or when the carrier serves as a diluent, it can be solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for tire active compound. The active compound can be adsorbed on a granular solid carrier, for example contained in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols,
-43WO 2017/152126
PCT/US2017/020792 polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent can include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
[0105] The formulations can be mixed with auxiliary agents which do not deleteriously react with the active compounds. Such additives can include wetting agents, emulsifying and suspending agents, salt for influencing osmotic pressure, buffers and/or coloring substances preserving agents, sweetening agents or flavoring agents. The compositions can also be sterilized if desired.
[0106] The route of administration can be any route which effectively transports the active compound of the invention which inhibits the activity of the IREla to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.
[0107] For parenteral administration, the earner will typically comprise sterile water, although other ingredients that aid solubility or serve as preservatives can also be included. Furthermore, injectable suspensions can also be prepared, in which case appropriate liquid carriers, suspending agents and the like can be employed, [0108] For topical administration, the compounds of the present invention can be formulated using bland, moisturizing bases such as ointments or creams.
[0109] If a solid carrier is used for oral administration, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation can be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
[WHO] Injectable dosage forms generally include aqueous suspensions or oil suspensions which can be prepared using a suitable dispersant or wetting agent and a suspending agent Injectable forms can be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils can be employed as solvents or suspending agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
..44..
WO 2017/152126
PCT/US2017/020792 [0111] For injection, the formulation can also he a powder suitable for reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations can optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds can be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection can be in ampoules or in multi-dose containers.
[0112] The formulations of the invention can be designed to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art. Thus, the formulations can also be formulated for controlled release or for slow release.
[0113] Compositions contemplated by the present invention can include, for example, micelles or liposomes, or some other encapsulated form, or can be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the formulations can be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections. Such implants can employ known inert materials such as silicones and biodegradable polymers, e.g., polylactide-polyglycolide. Examples of other biodegradable polymers include poly(orthoesters) and poly( anhydrides).
[0114] For nasal administration, the preparation can contain a compound of the invention which inhibits the enzymatic activity of the focal adhesion kinase, dissolved or suspended in a liquid carrier, preferably an aqueous carrier, for aerosol application. The carrier can contain additives such as solubilizing agents, e.g., propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabens.
[0115] For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhvdroxylated castor oil. [0116] Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
[0117] A typical tablet that can be prepared by conventional tableting techniques can contain:
Core:
Active compound (as free compound or salt thereof) Colloidal silicon dioxide (Aerosil)®
Cellulose, microcryst. (Avice!)®
Modified cellulose gum (Ac-Di-Sol)®
250 mg
1.5 mg 70 mg
7.5 mg
WO 2017/152126
PCT/US2017/020792
Magnesium stearate Ad.
Coating:
HPMC approx. 9 mg *Mywacett 9-40 T approx. 0.9 mg * Acylated monoglyceride used as plasticizer for film coating.
[0118] A typical capsule for oral administration contains compounds of the invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule. A typical injectable preparation is produced by aseptically placing 250 mg of compounds of the invention into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of sterile physiological saline, to produce an injectable preparation.
[0119] The compounds of the invention can be administered to a human in need of such treatment, prevention, elimination, alleviation or amelioration of a malcondition that is mediated through the action of IREla, for example, cancer, neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, or heart ischemia.
[0120] The pharmaceutical compositions and compounds of the present invention can generally he administered in the form of a dosage unit (e.g. tablet, capsule, etc.) in an amount from about 1 ng/kg of body weight to about 0.5 g/kg of body weight, or from about 1 μ/kg of body weight to about 500 mg/kg of body weight, or from about 10 μ/kg of body weight to about 250 mg/kg of body weight, most preferably from about 20 μ/kg of body weight to about 100 mg/kg of body weight. Those skilled in the art will recognize that the particular quantity of pharmaceutical composition and/or compounds of the present invention administered to an individual will depend upon a number of factors including, without limitation, the biological effect desired, the condition of the individual and the individual's tolerance for the compound.
[0121] The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 5000 mg, preferably from about 1 to about 2000 mg, and more preferably between about 2 and about 2000 mg per day can be used. A typical dosage is about 10 mg to about 1000 mg per day. In choosing a regimen for patients it can frequently he necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the activity of the compound, mode of administration, on the therapy desired, form in which administered, the subject to he treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge. IREla inhibitor bioactivity of the compounds of the invention can be determined by use of an in vitro assay system which measures tire activity of IREla, which can be expressed as EC50 or IC50 values, as ate well -46WO 2017/152126
PCT/US2017/020792 known in the art inhibitors of the invention can be determined by the method described in the
Examples.
[0122] Generally, the compounds of the invention are dispensed in unit dosage form including from about 0.05 mg to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.
[0123] Usually, dosage forms suitable for oral, nasal, pulmonal or transdermai administration include from about 125 pg to about 1250 mg, preferably from about 250 pg to about 500 mg, and more preferably from about 2.5 mg to about 250 mg, of the compounds admixed with a pharmaceutically acceptable carrier or diluent.
[0124] Dosage forms can be administered daily, or more than once a day, such as twice or thrice daily. Alternatively dosage forms can he administered less frequently than daily, such as every other day, or weekly, if found to be advisable by a prescribing physician.
[0125] An embodiment of the invention also encompasses prodrugs of a compound of the invention which on administration undergo chemical conversion by metabolic or other physiological processes before becoming active pharmacological substances. Conversion by metabolic or other physiological processes includes without limitation enzymatic (e.g, specific enzymatically catalyzed) and non-enzymatic (e.g., general or specific acid or base induced) chemical transformation of the prodrug into the active pharmacological substance. In general, such prodrugs will be functional derivatives of a compound of tire invention which are readily convertible in vivo into a compound of the invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
[0126] In another embodiment, there are provided methods of making a composition of a compound described herein including formulating a compound of the invention with a pharmaceutically acceptable carrier or diluent. In some embodiments, the pharmaceutically acceptable carrier or diluent is suitable for oral administration. In some such embodiments, the methods can further include the step of formulating the composition into a tablet or capsule. In other embodiments, the pharmaceutically acceptable carrier or diluent is suitable for parenteral administration. In some such embodiments, the methods further include the step of lyophilizing the composition to form a lyophilized preparation.
[0127] The compounds of the invention can be used therapeutically in combination with i) one or more other IREla inhibitors and/or ii) one or more other types of protein kinase inhibitors and/or one or more other types of therapeutic agents which can be administered orally in the same dosage form, in a separate oral dosage form (e.g., sequentially or non-sequentially) or hv injection together or separately (e.g., sequentially or non-sequentially).
..47..
WO 2017/152126
PCT/US2017/020792 [0128] Accordingly, in another embodiment the invention provides combinations, comprising:
a) a compound of the invention as described herein; and
b) one or more compounds comprising:
i) other compounds of the present invention, ii) other agents or medicaments adapted for treatment of a disease or malcondition for which inhibition of IREla is medically indicated, for example, vitamin E, an antioxidant, hydralazine, or any combination thereof. Such compounds, agents or medicaments can be medically indicated for treatment of cancers such as TNBC or ovarian cancer, neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, autoimmune diseases, brain ischemia, or heart ischemia.
[0129] Combinations of the invention include mixtures of compounds from (a) and (h) in a singb formulation and compounds from (a) and (b) as separate formulations. Some combinations of the invention can be packaged as separate formulations in a kit. In some embodiments, two or more compounds from (b) are formulated together while a compound of the invention is formulated separately.
[0130] The dosages and formulations for the other agents to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference, incorporated herein by reference.
[0131] The Examples illustrate some of experimental work performed in the development of the invention.
Example 1: Vitamin E and Hydrazine [0132] Consistently, both vitamin E and hydralazine suppressed pathological intracellular lipid accumulation in myeloid dendritic cells exposed to ovarian cancer ascites supernatants (Fig. 1). Based on the strong evidence linking aberrant iipid accumulation myeloid cell immunosuppression, these agents can be used to restore the function of antigen presenting cells in the tumor microenvironment.
Example 2; FRET Assay [0133] In addition to the indirect inhibitors vitamin E and hydralazine, the compositions and methods described herein can include one or more direct, small molecule IRE1 a inhibitors. [0134] IREla is a dual enzyme, containing a kinase and endoribonuclease domain. Phosphorylation of the kinase domain during times of ER stress leads to activation of the endoribonuclease domain and subsequent Xhpl splicing, indicating that small molecules „48..
WO 2017/152126
PCT/US2017/020792 designed to block either the kinase domain or the endoribonuclease domain are feasible inhibitory strategies.
[0135] To evaluate potential small molecule IRE1 inhibitors, a Forster resonance energy transfer (FRET)-based small molecule IRE1 screening system was used. In brief, a small XBP1-mimetic RNA hairpin containing sequence features required for IRE la-mediated splicing has been synthesized with the fluorophore 6FAM attached to the 5' end and the quenching dye Black Hole Quencher 1 (BHQ1) attached to the 3' end. When the hairpin is intact, 6FAM fluorescence is completely absorbed by BHQ1; however, IRE 1 α-mediated cleavage of the RNA hairpin leads to an increase in the fluorescence signal. The inventors also incorporated a point mutant version of this same RNA hairpin that is resistant to IRE la-mediated cleavage to control for non-specific RNAse contamination (Fig. 2).
Example 3: Potent IRE1a Inhibitors Identified by FRET Assay [0136] Approximately 170 compounds were obtained and evaluated using the FRET assay, and at least one active compound was identified from this screen (TC50: 26 μΜ, Fig. 3). Compound activity was evaluated at the biotechnology company Cyclofluidic guided entirely by the inventors.
[0137] A small panel of published type II kinase inhibitors structurally related to the FDAapproved kinase inhibitor Ponatinib (Desai et al., Med Chem 56(7): 3033-47 (2013)) were separately tested (Fig. 4 and Fig. 5). Several of these analogues displayed potent IRE1 a inhibitory activity first confirmed by FRET (Fig. 6) and later validated with several cellular assays that measure XBPl/IREla function (Fig. 7).
Example 4: Synthesis of IREla Inhibitors
The synthetic strategy used to generate many of the IREla inhibitors is shown in Figure 8 and Figure 9.
Example 5: Potent IREla Inhibitor Reduces Immunosuppressive Lipid Accumulation in Dendritic Cells and Inhibits Myeloid Cell Prostaglandin E2 Production [0138] The inventors have developed and tested dozens of structural analogues based around the Ponatinib-like compound series. The most potent of these compounds can reduce immunosuppressive lipid accumulation in dendritic cells and inhibit myeloid cell prostaglandin E2 production in vitro (Fig, 10).
WO 2017/152126
PCT/US2017/020792
Example 6: Computational Screening [0139] After establishing the FRET system, computational models of IRE la based on published crystal structures were used to dock over 7 million compounds commercially available from the company eMolecules. Docking was performed using the Schrodinger software suite.
[0140] The cytoplasmic domain of human IREla (approximately residues 465-977) has been crystallized five separate times (PDBs 4PL3, 4U6R, 4PL4, 4PL5, and 3P23) in different states of phosphorylation and activation, as well as with both endoribonuclease inhibitors and kinase inhibitors (Sanches et ah, Nature Communications 5:4202 (2014); Harrington et al., ACS Med Chem Letters 6:68-72 (2015); Ali et ah, The EMBO J 30:894-905 (2011)). These studies and others (see, e.g., Wang et ah, Nature Chem Biol 8:982-9 (2012)) provide substantial evidence that IREla kinase inhibitors can either inhibit or activate the IREla endoribonuclease domain depending on their binding mode.
[0141] Type I kinase inhibitors that lock the IREla kinase domain into a DFG-out conformation block endoribonuclease acti vity, while inhibitors that lock the kinase domain into a DFG-in conformation trigger mRNA splicing despite abrogating autophosphorylation.
[0142] All known endoribonuclease inhibitors bind to a shado w pocket in a highly solvent exposed manner at the IREla C-terminus, and make too few key binding contacts to effectively model computationally.
[0143] At the time this project was initiated, the only kinase inhibitor co-crystallized with IREla enforced a Type I, DFG-in configuration (PDB 4U6R). To generate a model of IREla in the target Type 11 DFG-out configuration, the inventors computationally grafted the DFG loop from the crystal structure of the SRC kinase bound to the type II inhibitor l-(4-(4-Amino-l-isopropyllH-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea onto the 4U6R 1RE1 crystal structure, as this compound also inhibits the IREla kinase and endoribonuclease domains. After grafting the SRC DFG-loop onto the IREla crystal structure, the SRC inhibitor was docked into the hybrid model for quality control.
[0144] The SRC inhibitor exhibited a good docking score using unconstrained rigid receptor docking, as its urea group made hydrogen bonds with both a serine residue N-terminal to the DFG loop and a lysine-aspartate salt bridge in the kinase active site. With the initial model validated, the set of all compounds commercially available from the company eMolecules (over 7 million in sum) was used as the screening collection. From the full list of 7 million compounds, only urea and amide-containing structures were computationally docked (-800,000 compounds), as these motifs form key hydrogen bond interactions with kinase DFG loops. Top scoring compounds were clustered by structural similarity and filtered for those with desirable properties, and the top scoring compounds from each of 49 clusters were ordered and tested by FRET assay.
-50WO 2017/152126
PCT/US2017/020792 [0145] Initial results indicated that one of the 49 compounds exhibited some activity against IRE1. The structure-activity relationships of an additional 62 compounds were examined. However, secondary screening after FRET assay optimization, performed at the CRO Cyclofluidic, revealed that none of these 111 compounds exerted any activity. Cyclo fluidic had published a small set of approximately 50 compounds(S) from their internal work on derivatives of the BCR-ABL kinase inhibitor Ponatinib, and the inventors also screened these published compounds for IREla inhibitory activity.
[0146] Serendipitously, the inventors identified the compounds shown in Figure 4 and Figure 5 from this additional effort.
[0147] New' crystal structures of IREla in complex with Type II, DFG-out-inducing kinase inhibitors became available (Concha et al., Molecular Pharmacol 88:1011-2 (2015)), which was used to develop a second model of IREla.
[0148] First, the ponatinib-like compounds were docked into this new' model, allowing some structural flexibility, to control for model quality. Subsequently, a second computational screen was performed with the updated model, and compounds for follow up were selected as follows:
1. Docked into the ponatinib-like compound induced structure.
2. H-bond with hinge NH
3. Strained compounds removed
4. Any compound with similarity to any of the known compounds tested thus far removed
5. Clustering
6. Selecting the highest docking score per cluster [0149] The top 63 compounds based on this strategy were then tested, and only one compound showed weak activity by FRET assay (Figure 3).
[0150] New small molecule compounds were designed to inhibit the human TRE1 alpha kinase domain. Multiple variants of the original compound series were designed and ranked by computational docking score using the software LiveDesign. High scoring compounds were synthesized and evaluated biochemically by the IREla FRET assay.
Example 8: In Vitro FRET Assay Protocol [0151] In vitro FRET assay was performed to evaluate the ability of select compounds to inhibit 1RE1, the results of which are summarized in the following table.
[0152] To perform the in vitro FRET assay, IX complete assay buffer (CAB; 1M D’TT, 50 mA! sodium citrate pH 7.15, ImM magnesium acetate, 0.02% tween 20) was used to dilute
-51WO 2017/152126
PCT/US2017/020792
SignalChem IREla protein to a final concentration of 2 nM. Selected compounds were serially diluted with DMSO in a non-binding black 384-well plate for a total of 15 μΐ in each well. 2 μΐ of the serially diluted compound or DMSO control were then added to new wells containing 98 μΐ of IX CAB, for a total volume of 100 μί, 10 μί of which were then transferred to wells of a new plate. 5 μΐ of the diluted IREla was then added to each well. 5μ1 of a 400 mM XBP1 RNA probe was then added to each well. Fluorescence was then read over 30 minutes in kinetic mode (485/515 nm).
[0153] Two RNA probes were used, XBP1 wildtype (CAUGUCCGC AGC AC AUG; SEQ ID NO: 1) which is able to be spliced by active IREla or XBP1 mutant (CAUGUCCGCAGCACAUG; SEQ ID NO: 2) which is unable to be spliced. Each probe contained a 5’ 6-FAM modification and a 3’ IOWA Black FQ modification.
Compound Ref. No. | Mean ECso | (nM) |
A25 | B |
A24 | B |
A23 | A |
A22 | A |
A21 | A |
A20 | A |
A19 | A |
A18 | C | |
A17 | A |
A16 | A |
A15 | B |
A14 | A |
A13 | A |
A12 | A i |
All | A |
A10 | A |
A9 | A |
A8 | A |
A8 | Β i |
A7 | B |
WO 2017/152126
PCT/US2017/020792
Compound Ref. No. | Mean ECso |
Aft | A |
A5 | A |
A4 | A |
A3 | A |
A2 | A |
Al | A |
Note: Biochemical assay Mean EC;o data are designated within the following ranges A: < 5000 nM
B: > 5000 nM to < 50000 nM
C: > 50000 nM to < 100000 nM
D: > 100000 nM
-53WO 2017/152126
PCT/US2017/020792
References
1. Wang, L., et al., Divergent allosteric control of the IRElalpha endoribonuclease using kinase inhibitors. Nat Chem Biol, 2012. 8(12): p. 982-9.
2. Harrington, P.E., et al., Unfolded Protein Response in Cancer: IRElalpha inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. ACS Med Chem Lett, 2015. 6(1): p. 68-72.
3. Concha, N.O., et al., Long-Range Inhibitor-Induced Conformational Regulation of Human IRElalpha Endoribonuclease Activity. Mol Pharmacol, 2015. 88(6): p. 1011-23.
4. Mendez, A.S., et al., Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. Elife, 2015. 4.
5. Cross, B.C., et al.. The molecular basis for selective inhibition of unconventional mRNA splicing by an IREl-binding small molecule. Proe Natl Acad Sci U S A, 2012. 109(15): p. E8 69-78.
6. Tang, C.H., et al., Inhibition ofER stress-associated IRE-1 /XBP-1 pathway reduces leukemic cell survival. J Clin Invest, 2014. 124(6): p. 2585-98.
7. Volkmann, K., et al., Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem, 2011.286(14): p. 12743-55.
8. Papandreou, I., et al., identification of an Irelalpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood, 2011.117(4): p. 1311-4.
9. Miniura, N., et al., Blockade ofXBPl splicing by inhibition of IRElalpha is a promising therapeutic option in multiple myeloma. Blood, 2012. 119(24): p. 5772-81.
10. Cubillos-Ruiz, J.R., et £il., ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell, 2015. 161(7): p. 1527-38.
11. Desai, B., et al., Rapid discovery of a novel series ofAbl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform.. J Med Chem, 2013. 56(7): p. 3033-47.
12. Sanches M, Duffy NM, Talukdar M, Thevakumaran N, Chiovitti D, Canny MD, et at Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE 1 endoribonuclease inhibitors. Nature communications. 2014;5:4202.
13. Harrington PE, Biswas K, Malwitz D, Tasker AS, Mohr C, Andrews KL, et al. Unfolded Protein Response in Cancer: IREJ alpha Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability. ACS medicinal chemistry letters. 2015;6:68-72.
..54..
WO 2017/152126
PCT/US2017/020792
14. All MM, Bagratuni T, Davenport EL, Nowak PR, Silva-Santisteban MC, Hardcastle A, et al. Structure of the Irel autophosphorylation complex and implications for the unfolded protein response. The EMBO journal. 2011 ;30:894~i905.
15. Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeiiger MA, et al. Divergent allosteric control of the IRElalpha endoribonuclease using kinase inhibitors. Nature chemical biology. 2012;8:982-9.
16. Desai B, Dixon K, Farrant E, Feng Q, Gibson KR, van Hoorn WP, et al. Rapid discovery of a novel series ofAbl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. Journal of medicinal chemistry. 2013;56:3033-47.
17. Concha NO, Smallwood A, Bonnette W, Totoritis R, Zhang G, Federowicz K, et al. Long-Range Inhibitor-Induced Conformational Regulation of Human IRElalpha Endoribonuclease Activity. Molecular pharmacology. 2015;88:1011-23.
[0154] All patents find publications referenced herein are hereby specifically incorporated by reference to the same extent as if it had been incorporated by reference in its entirety individually or set forth herein in its entirety. Applicants reserve the right to physically incorporate into this specification any and all materials and information from any such cited patents or publications. [0155] Additional Embodiments [0156] The following exemplary embodiments are provided, the numbering of which is not to be construed as designating levels of importance:
[0157]
Embodiment 1 provides a compound of formula I:
wherein:
A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x Ri substituents;
C is phenyl or pyridinyl;
D is heterocyclyl ring;
linkagei is a Ci-Cs alkylene, an alkenylene, an alkynylene, an alkylamido, an acyl, or an oxo(carbonyl)alkylene with a first and second terminal atom;
linkage2 is a C1-C3 alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyi with a first and second terminal atom.;
WO 2017/152126
PCT/US2017/020792 y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;
x is an integer of 0-2; v is an integer of 0-1;
Ri substituents on the A ring are selected from amino, C3-C3 alkyl, ether, alkoxy, oxy, hydroxy, -NH-SCh-phenyi-fRs), and cyano;
R2 substituents on the B ring are selected from amino, and C1-C3 alkyl;
R3 substituents on the C ring are selected from CF3, and C1-C3 alkyl; and
R4 substituents on the D ring are selected from C1-C3 alkyl, Ci-Cs alkoxy, benzyl, and benzaldehyde;
R5 is halo; or a pharmaceutically acceptable salt thereof.
[0158] Embodiment 2 provides the compound of embodiment 1, where the A ring is hetero aromatic.
[0159] Embodiment 3 provides a compound of any one of embodiments 1 or 2, where the A ring is a fusion of two rings.
[0160] Embodiment 4 provides a compound of any one of embodiments 1-3, where the A ring is indazole, imadazopyridine, imadazopyrazine, imadazopyridazine, pyrrolopyridine, hexahydrothienopyrimidine, imidazole, pyrazole, pyrazine, pyridine, pyrimidine, phenylpyrimidinamine, quinolinyl, isoquinolinyl, and tetrahydroquinolinyl.
[0161] Embodiment 5 provides a compound of any one of embodiments 1-4, where the A ring is selected from:
H
N/ , V-N· •-to to /'Ά Ά
C ·' \ O- >, , .
N' to to
As'
N A?
· ·· -to
-to to^.
Vn
Ν'*'
A .to to.
ΆΑ ]
I
Nf
-56WO 2017/152126
PCT/US2017/020792
Ά .-gfi . :4.. .A
H
X .„fi
H „N %/
x.
and
XX
Χί^ [0162] Embodiment 6 provides a compound of any one of embodiments 1-5, where the B ring is a single, noil-fused ring.
[0163] Embodiment 7 provides a compound of any one of embodiments 1-5, where the B ring is a fusion of two rings.
[0164] Embodiment 8 provides a compound of any one of embodiments 1-7, where the B ring is selected from:
/”X cr ,/A^
X.
i IN
IE .Nil and wxy z\
X \ \
/
-NH
Embodiment 9 provides a compound of any one of embodiments 1-8, wherein linkage! is selected from:
O
-57WO 2017/152126
PCT/US2017/020792 and o , wherein a hydrogen atom on Ring A is replaced by the first terminal atom of linkage! and a hydrogen atom on Ring B is replaced by the second terminal atom of linkage!.
[0166] Embodiment 10 provides a compound of any one of embodiments 1--9, wherein the C ring is phenyl.
[0167] Embodiment 11 provides a compound of any one of embodiments 1-10, wherein the linkage2 is selected from:
H
TO
TO %·
H
TO and 0 , wherein a hydrogen atom on Ring B replaced by the first terminal atom of linkage2 and a hydrogen atom on Ring C is replaced by the second terminal atom of linkage2. [0168] Embodiment 12 provides a compound of any one of embodiments 1-11, wherein D ring is selected from
[0169] Embodiment 13 provides a compound of any one of embodiments 1 -12, where the Rl substituents on the A ring are selected from amino and C1-C3 alkyl.
[0170] Embodiment 14 provides a compound of any one of embodiments 1-13, where the Rl substituents on the A ring are selected from -NH2 and CH3.
[0171] Embodiment 15 provides a compound of any one of embodiments 1-14, with x=0. [0172] Embodiment 16 provides a compound of any one of embodiments 1-14, with x=l.
-58WO 2017/152126
PCT/US2017/020792 [0173] Embodiment 17 provides a compound of any one of embodiments 1-15, with x=0 when the A ring is a fusion of two rings.
[0174] Embodiment 18 provides a compound of any one of embodiments 1-14, with x=l or 2 when the A ring is a single, nonfused ring.
[0175] Embodiment 19 provides a compound of any one of embodiments 1-18, wherein the R3 substituent on the C ring is CF3.
[0176] Embodiment 20 provides a compound of any one of embodiments 1-18, wherein the R4 substituents on the D ring are selected from CH3, CH3CHCH3, CH3CH(CH2)CH.3, and CH3CH2CH3OH.
[0177] Embodiment 21 provides a compound of formula II:
wherein:
E is phenyl;
F is phenyl, naphthalene, tetrahydronaphthalene, or a bicyclic heterocycle;
G is phenyl, or a heterocyclyl ring; heterocycle indene, dihydroindene, or benzodioxole; linkages is a C1-C3 alkyl, alkylamino, aminoalkyl, alkylaminoalkylene, or amino; linkage4 is aikylamido, amidoalkyl, alkylamidoalkylene;
R2 is amino, or C1-C3 alkyl;
R5 is halo;
Rt, is C1-C3 alkyl, C1-C3 alkoxy, or hydroxy;
x is an integer of 0-2;
v is an integer of 0-1; or a pharmaceutically acceptable salt thereof.
[0178] Embodiment 22 provides a compound from any of the compounds in the Examples, or pharmaceutically acceptable salts thereof.
[0179] Embodiment 23 provides a compound of any one of embodiments 1-22, pharmaceutically acceptable salts thereof, or any combination of such compounds or salts.
[0180] Embodiment 24 provides a compound of embodiment 23, further comprising vitamin E, an antioxidant, hvdralazine. or anv combination thereof.
[0181] Embodiment 25 provides a method comprising administering the composition of any one of embodiments 23 or 24 to a mammal.
[0182] Embodiment 26 provides a method of embodiment 25, wherein the mammal is in need of administration of the composition.
WO 2017/152126
PCT/US2017/020792 [0183] Embodiment 26 provides a method of any one of embodiments 25 or 26, wherein the mammal has cancer, a neurodegenerative disease, inflammation, a metabolic disorder, liver dysfunction, an autoimmune disease, brain ischemia, or heart ischemia.
[0184] Embodiment 27 provides a method of any one of embodiments 25-27, wherein the mammal has triple negative breast cancer or ovarian cancer.
[0185] Embodiment 28 provides a compound of any one of embodiments 1--22 for use in treating cancer.
[0186] Embodiment 29 provides a use of a compound of any one of embodiments 1-22 for treating cancer.
[0187] The specific compositions and methods described herein are representative, exemplary and not intended as limitations on the scope of the invention. Other objects, aspects, and embodiments will occur to those skilled in the art upon consideration of this specification, and are encompassed within the spirit of the invention as defined by the scope of the claims. It will he readily apparent to one skilled in the art that varying substitutions and modifications may he made to the invention disclosed herein without departing from the scope and spirit of the invention. The terms and expressions that have been employed are used as terms of description and not of limitation, and there is no intent in the use of such terms and expressions to exclude any equivalent of the features shown and described or portions thereof, but it is recognized that various modifications arc possible within the scope of the invention as claimed. Thus, it will be understood that although the present invention has been specifically disclosed by embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims and statements of the invention.
[0188] The invention illustratively described herein may be practiced in the absence of any element or elements, or limitation or limitations, which is not specifically disclosed herein as essential. The methods and processes illustratively described herein may be practiced in differing orders of steps, and the methods and processes fire not necessarily restricted to the orders of steps indicated herein or in the claims.
[0189] As used herein and in the appended claims, the singular forms a, an, and the include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to a compound or a catalyst or a ligand includes a plurality of such compounds, catalysts or ligands, and so forth. In this document, the term or is used to refer to a nonexclusive or, such that A or B includes A hut not Β, B hut not A, and A and B, unless otherwise indicated.
WO 2017/152126
PCT/US2017/020792 [0190] Under no circumstances may the patent be interpreted to be limited to the specific examples or embodiments or methods specifically disclosed herein. Under no circumstances may the patent be interpreted to be limited by any statement made by any Examiner or any other official or employee of the Patent and Trademark Office unless such statement is specifically and without qualification or reservation expressly adopted in a responsive writing by Applicants. [0191] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0192] The Abstract is provided to comply with 37 C.F.R. § 1.72(b) to allow the reader to quickly ascertain the nature and gist of the technical disclosure. The Abstract is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. [0193] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
[0194] Additional embodiments of the invention are found in the following listing of compounds:
WO 2017/152126
PCT/US2017/020792
Claims (13)
- WHAT IS CLAIMED IS:1. A method of inhibiting IREal comprising:contacting IREal with a compound of formula (I)A\ Z A\A HinkageJ B XA A. A «gea-i c \ A \ wherein:A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x Ri substituents;C is phenyl or pyridinyl;D is heterocyclyl ring;linkagei is a C1-C5 alkylene, an alkenylene, an alkynylene, an aikylamido, an acyl, or an oxo(carbonyl)alkylene with a first and second terminal atom;linkage2 is a C1-C3 aikylamido, amidoaikyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;x is an integer of 0-2; v is an integer of 0-1;Ri substituents on the A ring are selected from amino, C1-C3 alkyl, ether, alkoxy, oxy, hydroxy, -NH-SO2-phenyl-(R5), and cyano;R2 substituents on the B ring are selected from amino, and C1-C3 alkyl;R3 substituents on the C ring are selected from CF3, and C1-C3 alkyl; and R4 substituents on the D ring fire selected from C1-C3 alkyl, C1-C3 alkoxy, benzyl, and benzaldehyde;R5 is halo; or a pharmaceutically acceptable salt thereof,
- 2. The method of claim 2, further comprising vitamin E, an antioxidant, a hydralazine, or any combination thereof.
- 3. The method of claim 1, further comprising a pharmaceutical composition comprising at least one compound of formula (I), a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
- 4. The method of claim 3, further comprising administering the composition to a mammal in need thereof.-62WO 2017/152126PCT/US2017/020792
- 5. The method of claim. 3, wherein the composition is suitable for oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or topical administration.
- 6. The method of claim 1, further comprising treating a condition selected from the group consisting of neurodegenerative diseases, inflammation, metabolic disorders, liver dysfunction, brain ischemia, heart ischemia, autoimmune diseases, and cancer.
- 7. The method of claim. 6, wherein the cancer is ovarian cancer or triple negative breast cancer.
- 8. The method of claim 3, wherein the composition enhances dendritic cell and T cell anti-tumor activity in mammals.
- 9. The method of claim 3, wherein the composition blocks myeloid cell immunosuppression mediated by tumor-associated factors.
- 10. The method of claim. 1, wherein the compound is selected from the group consisting of Compound 31, Compound 36, Compound 41, Compound 42, Compound 43, and Compound 44.
- 11. The method of claim 1, wherein, the compound is selected from any of the compounds in the Examples, and any combinations thereof.
- 12. A compound of formula (I):wherein:A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x Ri substituents;C is phenyl or pyridinyl;D is heterocyclyl ring;linkagei is a G-Cs alkylene, an alkenylene, an alkynylene, an alkylamido, an acyl, or an oxo(carbonyl)alkylene with a first and second terminal atom;linkage2 is a C1-C3 alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;x is an integer of 0-2;WO 2017/152126PCT/US2017/020792 v is an integer of 0-1;R. substituents on the A ring Eire selected from amino, C1-C3 alkyl, ether, alkoxy, oxy, hydroxy, -NH-SO2-phenyl-(Rs), and cyano;R2 substituents on the B ring are selected from amino, and C1-C3 alkyl;Rs substituents on the C ring are selected from CF3, and C1-C3 alkyl; and R4 substituents on the D ring are selected from C1-C3 alkyl, C1-C3 alkoxy, benzyl, and benzaldehyde;Rs is halo; or a pharmaceutically acceptable salt thereof for use in treating cancer.
- 13. Use of a compound of formula (I):.ARA AAA z AA HinkageJ B XA A AAX «gea-i c A:hA \ A \AAA d ) wherein:A and B are separately each a heterocyclyl ring or a phenyl group, where the A ring has x Ri substituents;C is phenyl or pyridinyl;D is heterocyclyl ring;linkage! is a C1-C5 alkylene, an alkenylene, an alkynyl ene, an alkylamido, an acyl, or an oxo(carbonyl)alkylene with a first and second terminal atom;linkage2 is a C1-C3 alkylamido, amidoalkyl, amino, urea, alkylurea, or ureaalkyl with a first and second terminal atom;y is an integer of 0-3, and when y is 0, the linkage between the rings is a single bond;x is an integer of 0-2;v is an integer of 0-1;Ri substituents on the A ring are selected from amino, C1-C3 alkyl, ether, alkoxy, oxy, hydroxy, -NH-SCh-phenyl-fRs), and cyano;R2 substituents on the B ring are selected from amino, and C1-C3 alkyl;Rs substituents on the C ring are selected from CF3, and C1-C3 alkyl; and R4 substituents on the D ring fire selected from C1-C3 alkyl, C1-C3 alkoxy, benzyl, and benzaldehyde;R5 is halo; or a pharmaceutically acceptable salt thereof for treating cancer.WO 2017/152126PCT/US2017/0207921/1180$80$FIG. 1A . . k.aS'X x r r / iH./ZFIG, 1BΛΑ relatives) M* ΛΜθμΙοΜS>PFIG. IGWO 2017/152126PCT/US2017/0207922/11 *25% ovarian cancer ascites8odipyi0593 *FIG.1DWO 2017/152126PCT/US2017/0207923/11RE 1 ifef £ A^Quenching released, tessenceemledFIG. 2BWO 2017/1521264/11PCT/US2017/020792 \ ί //ί.'ϊ jt··'K ,// 'NF a ······ M AlFIG, 3-K-'K? }.&?;WO 2017/1521265/11PCT/US2017/020792Compound 31 1CS0 - 229 nMCompound 36 Ο0-δ57ηΜ /Compound 41 ASO-243 nMCompound 42 ASO - 196 π MWO 2017/152126PCT/US2017/0207926/11Compound 43 Compound 44ICSO = 43 nM ICSO = 112 nMFIG. 5WO 2017/152126PCT/US2017/0207927/11FIG. 6WO 2017/152126PCT/US2017/0207928/11A.+ 1 yg/mL tunicamycinO ωSQ
03 O o - 03 — 03 03 — 03 T“ —' o o O o O O kJ •—- i£> τ— τ— τ— τ— ·,— τ— ω o —' — -— — — -— 00 ‘V ·,— τ— CN co co co XT XT Q Nt o O o O O o B.+ 1 ug/mL tunicamycinIRE1 (phostag) orn kj jFIG. 7 «— Phosphorylated «— DephosphorylatedWO 2017/152126PCT/US2017/0207929/11->OMWO 2017/152126PCT/US2017/02079210/111WCVC ' ‘-NS:'%Afeg btedCFIG. 9WO 2017/152126PCT/US2017/02079211/11
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662303236P | 2016-03-03 | 2016-03-03 | |
US62/303,236 | 2016-03-03 | ||
US201662303951P | 2016-03-04 | 2016-03-04 | |
US62/303,951 | 2016-03-04 | ||
PCT/US2017/020792 WO2017152126A1 (en) | 2016-03-03 | 2017-03-03 | Small molecule ire1-alpha inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2017228405A1 true AU2017228405A1 (en) | 2018-10-18 |
AU2017228405A8 AU2017228405A8 (en) | 2018-11-01 |
Family
ID=58348003
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017228405A Abandoned AU2017228405A1 (en) | 2016-03-03 | 2017-03-03 | Small molecule IRE1-alpha inhibitors |
AU2017228398A Abandoned AU2017228398A1 (en) | 2016-03-03 | 2017-03-03 | Small molecule IRE1-alpha inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017228398A Abandoned AU2017228398A1 (en) | 2016-03-03 | 2017-03-03 | Small molecule IRE1-alpha inhibitors |
Country Status (6)
Country | Link |
---|---|
US (4) | US20170252350A1 (en) |
AU (2) | AU2017228405A1 (en) |
BR (1) | BR112018067538A2 (en) |
CA (2) | CA3016161A1 (en) |
IL (2) | IL261385A (en) |
WO (2) | WO2017152117A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3291679T3 (en) * | 2015-05-06 | 2022-04-25 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
US20170252350A1 (en) | 2016-03-03 | 2017-09-07 | Cornell University | Small molecule ire1-alpha inhibitors |
CA3044259A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
WO2018161033A1 (en) * | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
WO2018222918A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
WO2018222917A1 (en) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
EP3675858B1 (en) | 2017-09-01 | 2023-04-26 | OptiKira, LLC | Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition |
KR20190043437A (en) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | Heterocylic compound as a protein kinase inhibitor |
WO2019094641A1 (en) | 2017-11-10 | 2019-05-16 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
WO2019195135A1 (en) * | 2018-04-01 | 2019-10-10 | The Wistar Institute | Substituted chromenones, ire1 inhibitors, and methods of using same |
EP4201924A1 (en) * | 2018-12-03 | 2023-06-28 | Cornell University | Ire1 small molecule inhibitors |
KR20210139280A (en) * | 2019-02-27 | 2021-11-22 | 옵티키라 엘엘씨 | Pyrazolopyridine compound for the inhibition of IR1 |
WO2020191227A1 (en) * | 2019-03-20 | 2020-09-24 | Cornell University | Methods for controlling prostaglandin-mediated biological processes |
EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
WO2021158516A1 (en) * | 2020-02-03 | 2021-08-12 | Nimbus Iaso, Inc. | IRE1α MODULATORS AND USES THEREOF |
JP7461605B2 (en) | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | Quinoline Compounds |
CN115947693A (en) * | 2022-12-18 | 2023-04-11 | 重庆医科大学 | FGFR4 inhibitor and preparation and application thereof |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
ZA985247B (en) * | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
US6391891B1 (en) * | 1997-08-09 | 2002-05-21 | Smithkline Beecham Plc | Bicyclic compounds as ligands for 5-HT1 receptors |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
GB0320244D0 (en) * | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
UY28931A1 (en) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | USED PIRROLOTRIAZINE DERIVATIVES TO TREAT HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS |
US20080261952A1 (en) * | 2004-08-16 | 2008-10-23 | Jason Bloxham | Aryl Urea Derivatives for Treating Obesity |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
JP5197016B2 (en) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ, エルエルシー | Enzyme modulators and therapy |
US20060281771A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
US20090227588A1 (en) | 2005-12-05 | 2009-09-10 | Roman Wolfgang Fleck | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors |
DK2495016T3 (en) | 2005-12-23 | 2019-12-16 | Ariad Pharma Inc | Bicyclic heteroaryl compounds |
PE20070978A1 (en) * | 2006-02-14 | 2007-11-15 | Novartis Ag | HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) |
EP2639231B1 (en) * | 2006-04-26 | 2019-02-06 | Idemitsu Kosan Co., Ltd. | Aromatic amine derivative, and organic electroluminescence element using the same |
EP1867648A1 (en) * | 2006-06-13 | 2007-12-19 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. |
PE20080906A1 (en) * | 2006-08-17 | 2008-07-05 | Kemia Inc | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS |
WO2008054702A1 (en) * | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
WO2008071456A2 (en) * | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
KR20090031122A (en) | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | Compounds containing indazole frameworks, preparing method thereof and pharmaceutical composition containing thereof |
WO2009065096A1 (en) | 2007-11-16 | 2009-05-22 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
EP2277881A4 (en) * | 2008-04-18 | 2011-09-07 | Shionogi & Co | Heterocyclic compound having inhibitory activity on p13k |
KR101061599B1 (en) * | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | Novel indazole derivatives that are protein kinase inhibitors for the treatment of abnormal cell growth diseases, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as active ingredients |
JPWO2010125799A1 (en) | 2009-04-27 | 2012-10-25 | 塩野義製薬株式会社 | Urea derivatives having PI3K inhibitory activity |
EP2470183B1 (en) | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
WO2011047384A2 (en) * | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
EP2532661A1 (en) * | 2011-06-10 | 2012-12-12 | Syngenta Participations AG | Novel insecticides |
CA2852936A1 (en) * | 2011-10-20 | 2013-04-25 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
CN103664787B (en) | 2012-09-17 | 2015-09-09 | 南京圣和药业股份有限公司 | Alkynes heteroaromatic ring compounds and application thereof |
MX2015003874A (en) | 2012-09-26 | 2015-12-16 | Univ California | Modulation of ire1. |
CN104870446B (en) * | 2012-11-07 | 2019-08-13 | 内尔维阿诺医学科学有限公司 | Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, preparation method and its purposes as kinase inhibitor |
CN103848829B (en) | 2012-11-28 | 2017-04-12 | 南京圣和药业股份有限公司 | Heteroaryl alkyne compounds and application thereof |
KR102098093B1 (en) * | 2012-12-06 | 2020-04-08 | 덕산네오룩스 주식회사 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof |
WO2015049325A1 (en) * | 2013-10-03 | 2015-04-09 | F. Hoffmann-La Roche Ag | Therapeutic inhibitors of cdk8 and uses thereof |
GB2522226A (en) * | 2014-01-17 | 2015-07-22 | Agency Science Tech & Res | Heteroaryl alkyne derivatives and uses thereof |
CA2960730A1 (en) * | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds as rearranged during transfection (ret) inhibitors |
WO2017015217A2 (en) | 2015-07-20 | 2017-01-26 | Velo3D, Inc. | Transfer of particulate material |
US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
US20170252350A1 (en) | 2016-03-03 | 2017-09-07 | Cornell University | Small molecule ire1-alpha inhibitors |
CN107176951A (en) | 2016-03-11 | 2017-09-19 | 恩瑞生物医药科技(上海)有限公司 | A kind of carbamide compounds, its preparation method and its medical usage |
WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
-
2017
- 2017-03-03 US US15/449,610 patent/US20170252350A1/en not_active Abandoned
- 2017-03-03 AU AU2017228405A patent/AU2017228405A1/en not_active Abandoned
- 2017-03-03 BR BR112018067538A patent/BR112018067538A2/en not_active IP Right Cessation
- 2017-03-03 US US15/449,547 patent/US10125123B2/en active Active
- 2017-03-03 CA CA3016161A patent/CA3016161A1/en not_active Abandoned
- 2017-03-03 CA CA3016196A patent/CA3016196A1/en not_active Abandoned
- 2017-03-03 WO PCT/US2017/020773 patent/WO2017152117A1/en active Application Filing
- 2017-03-03 AU AU2017228398A patent/AU2017228398A1/en not_active Abandoned
- 2017-03-03 WO PCT/US2017/020792 patent/WO2017152126A1/en active Application Filing
-
2018
- 2018-08-26 IL IL261385A patent/IL261385A/en unknown
- 2018-08-29 US US16/116,065 patent/US10988461B2/en active Active
- 2018-09-03 IL IL261557A patent/IL261557A/en unknown
-
2021
- 2021-03-30 US US17/217,599 patent/US20210238167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170252350A1 (en) | 2017-09-07 |
CA3016196A1 (en) | 2017-09-08 |
US20170253590A1 (en) | 2017-09-07 |
IL261385A (en) | 2018-10-31 |
IL261557A (en) | 2018-10-31 |
US10125123B2 (en) | 2018-11-13 |
CA3016161A1 (en) | 2017-09-08 |
WO2017152126A1 (en) | 2017-09-08 |
US10988461B2 (en) | 2021-04-27 |
AU2017228405A8 (en) | 2018-11-01 |
US20210238167A1 (en) | 2021-08-05 |
BR112018067538A2 (en) | 2019-02-05 |
WO2017152117A1 (en) | 2017-09-08 |
AU2017228398A1 (en) | 2018-10-18 |
US20190016706A1 (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017228405A1 (en) | Small molecule IRE1-alpha inhibitors | |
WO2018161033A1 (en) | Small molecule ire1-alpha inhibitors | |
US9586928B2 (en) | Modulators of the nuclear hormone receptor ROR | |
CA2780433C (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
AU2015292356B2 (en) | Novel GLP-1 receptor modulators | |
WO2009017954A1 (en) | Inhibitors of jak2 kinase | |
ES2758841T3 (en) | Selective heterocyclic sphingosine-1-phosphate receptor modulators | |
WO2011115892A1 (en) | Modulators of the retinoic acid receptor-related orphan receptors | |
US8957093B2 (en) | N-biphenylmethylindole modulators of PPARG | |
CA2857197A1 (en) | Novel glp-1 receptor modulators | |
EA021672B1 (en) | Modulators of sphingosine-1-phosphate receptors and use thereof | |
US10118915B2 (en) | Kappa opioid ligands | |
WO2008150446A1 (en) | Inhibitors of protein kinases | |
EP2670245B1 (en) | Alpha-ketoheterocycles and methods of making and using | |
US9493464B2 (en) | Wee1 degradation inhibitors | |
CA3008485A1 (en) | Alkynyl dihydroquinoline sulfonamide compounds | |
WO2014116684A1 (en) | Non-peptidic neuropeptide y receptor modulators | |
US20150246908A1 (en) | Klf5 modulators | |
WO2022093817A1 (en) | Macrophage migration inhibitory factor inhibitors, and methods of making and using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: CORNELL UNIVERSITY Free format text: FORMER APPLICANT(S): RUIZ, JUAN RODRIGO CUBILLOS; GLIMCHER, LAURI; BETTIGOLE, SARAH; CORNELL UNIVERSITY |
|
TH | Corrigenda |
Free format text: IN VOL 32 , NO 40 , PAGE(S) 5608 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME LAURI H. GLIMCHER; CORNELL UNIVERSITY; SARAH ELIZABETH BETTIGOLE; JUAN RODRIGO CUBILLOS RUIZ, APPLICATION NO. 2017228405, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO LAURIE H. GLIMCHER |
|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |